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Zerumbone (ZER) is a sesquiterpene derived from Zingiber zerumbet smith, family Zingiberaceae. It has 
been shown to possess anti-cancer and apoptosis-inducing properties against various human tumour 
cells as well as in vivo against a number of induced malignancies in mice. In this study a simple, 
specific and accurate high performance liquid chromatographic method for determination of ZER in 
micro-volumes human plasma (| 1.5 ml) was developed and validated. ZER and its analogue -Humulene 
as internal standard were easy recovered by simple one step plasma protein precipitation using 
acetonitrile and separated in isocratic mobile phase, on reverse phase-C18 column. The effluent was 
monitored by Photodiode Array (PDA) detector and at a flow rate of 1.0 ml/min. The linearity of 
proposed method was 2 – 15 µg/ml. The intra-day and inter-day coefficient of variation and percent error 
values of the method were less than 15% and mean recovery was more than 90% for both ZER and -
Humulene. This method was found to be precise, specific, accurate and robust for detection and 
analysis of ZER in human plasma. 
 





Zingiber zerumbet (L.) smith, known as lempoyang, is a 
member of the family Zingiberaceae, used in the tradi-
tional medicine as a cure for swelling, sores, loss of 
appetite and worm infestation in children (Somchit and 
Nur-Shakirah, 2003). In some Southeast Asian countries, 
the rhizomes of the plant are employed in traditional 
medicine as anti-inflammation, while the young shoots 
and inflorescence are used as condiments (Murakami et 
al., 2002). This plant has been shown to have anti-tumor 
(Sakinah et al., 2007), anti-inflammatory (Murakami et al., 




*Corresponding author. E-mail: ahmadbstmm@yahoo.com or 
adelalzubairi@hotmail.com. Tel: +603-89462124 Fax: +603-
89462101. 
(Tanaka et al., 2001). Zerumbone (ZER) is a bioactive 
crystalline monocyclic sesquiterpene derived from zingiber 
zerumbet rhizomes. It exhibits variety of interesting  reac-
tions, such as region-and regeoselective conjugates addi-
tions, transannular ring contraction, cyclization and several 
regeospecific reactions which cleave the 11-membered 
ring (Kitayama et al., 1999, 2001; Ohe et al., 2000). This 
bioactive component has its unique structure, with cross-
conjugated ketone in an 11-membered ring, as well as 
remarkable biological activities. It has been reported that 
ZER constitutes about 37% of Z. zerumbet (Matthes et 
al., 1980; Sakinah et al., 2007). Moreover, this compound 
showed a potential candidate for the development of anti-
cancer treatment of natural origin.  
ZER has been previously identified as distinct 
suppressor of tumor promoter 12-O-tetradecanoyl-
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(EBV) activation in Raji cells (Murakami et al., 1999).  
Murakami et al. (2004) reported that ZER inhibits the 
proliferation of colon and skin cancer cells through 
apoptosis, while having less effect on normal cells 
proliferation (Murakami et al., 2002; Murakami et al., 
2004).  Recently, ZER was reported to suppress the 
development of cervical intraepithelial neoplasia in 
mouse (Abdul et al., 2008). ZER has gained a great 
attention due to its activity towards many diseases in vitro 
and in vivo. Very recently, Sung et al. (2009) reported 
ZER as modulator for osteoclastogenesis induced by 
Receptor Activator for Nuclear Factor  B Ligand 
(RANKL) and breast cancer (Sung et al., 2009).  In 
addition ZER was reported to effectively suppress mouse 
colon and lung carcinogenesis through multiple 
modulatory mechanisms (Kim et al., 2009).  
However, to the best of our knowledge, no 
chromatographic method has been described in literature 
for ZER determination in human plasma as well as other 
biological fluids.  Here, we present for the first time an 
easy, HPLC method for determination of ZER in human 
plasma which requires minor laboratory efforts. This 
method is one step plasma protein precipitation followed 
by injection into HPLC with Photodiode Array (PDA) 
detector which is available in most analytical laboratories. 








ZER was extracted from Zingiber zerumbet rhizomes obtained from 
the wet market in Kuala Lumpur, Malaysia. The purity of the 
extracted ZER was > 98%. Structurally similar, -Humulene (HUM) 
(Figure 1 (A) and (B)) was used as internal standard (IS) and was 
purchased from Sigma Chemical Co. (Street Louis, MO, USA). 
HPLC grade acetonitrile, methanol and potassium dihydrogen 
orthophosphate monobasic were purchased from Fisher Scientific 
(USA). Ultra pure water was used throughout the experiment.  




Standard preparation and quality control  
 
Stock and working solutions of ZER and HUM (100 µg/ml) was 
prepared by dissolving in acetonitrile. Standard solutions of ZER in 
human plasma were prepared by spiking the diluted stock solution, 
to give the final concentrations of 2, 4, 6, 8, 10 and 15 µg/ml. The 





HPLC apparatus and chromatographic conditions  
 
HPLC system consist of Alliance separation module model e2695 
with PDA detector, the signals were processed by Empower™ 
software (Waters, Milford, MA, USA). The mobile phase composed 
of acetonitrile: methanol: 0.01 M potassium dihydrogen 
orthophosphate (25: 55: 20). The analytical column used was C18 
(Symmetry, 250 X 4.6 mm ID, 5 µm particles size) at an ambient 
temperature. The elute was monitored by PDA detector at a flow 
rate of 1 ml /min in wavelength of 254 nm. 
 
 
Sample preparation  
 
Ten microliters of internal standard solution 50 µg/ml were added to 
150 µl plasma sample in microcentrifuge tube. The tube was vortex 
for 1 min and 200 µl of acetonitrile was added and vortexed for 2 - 4 
min to precipitate the plasma protein, then the sample was 
centrifuged at 10000 rpm for 15 min. The supernatant was 




Validation procedure   
 
The validation parameters obtained were specificity, linearity, 
accuracy, precision, stability and robustness. The method was 





Specificity was obtained by comparing chromatograms of 6 different 
batches of blank plasma obtained from 6 different subjects and 
plasma samples spiked with ZER and HUM.  
 
 
Linearity and lower limit of quantification (LOQ)  
 
Calibration plots were constructed from blank plasma spiked with 
HUM and six concentrations of ZER (2 – 15 µg/ml). The linearity of 
each calibration curve was determined by plotting the peak area 
ratio(y) of ZER to HUM vs the nominal concentration (x) of ZER. 
The calibration curves were constructed by weighted (1/x) least –
square linear regression method. The lower limit of quantitation 
(LOQ) is the lowest concentration of the analyte that can be 
determined with acceptable precision and accuracy.  
 
 
Precision and accuracy  
 
The intra-day and inter-day precision and accuracy of the method 
were determined by percent coefficient of variation (% CV) and 
percentage relative error (% RE) respectively, according to the 
reported guidelines (FDA guidance for industry, 2001; Shah et al., 
2000). Quality Control (QC) samples containing 3, 7 and 12 µg/ml 
concentrations   were   spiked   for  determination  of  precision  and  




Table 1. Intra- and Inter-day precision and accuracy of ZER in human plasma. 
 
Calculated Conc. (µg/ml) C.V.% % Error Nominal Conc. (µg/ml) 
Intra-day Inter-day Intra-day Inter-day Intra-day Inter-day 
3 2.98 2.85 3.47 7.46 -0.62 -4.89 
7 7.13 6.77 2.43 5.71 1.79 -3.26 




accuracy. Three replicates at each concentration were processed 
as described in the sample preparation on day 1, 2, 3 and 15 to 
determine intra-day and inter-day precision and accuracy. The % 
RE values were calculated by the following equation:  
 
[(CC - AC) / AC] X 100 
 





The recovery of ZER was determined for QC samples  at  the  three 
samples pools 3, 7, 12 µg/ml. Three replicates of each QC sample 
were treated as mentioned in the sample preparation previously 
and injected into HPLC system. The extraction recovery was 
calculated by the following equation:  
 
Recovery = [(peak area after extraction) / (peak area after direct 





The stability studies were carried out at the three different concen-
trations of the QC values (3, 7, 12 µg/ml) stored at room 
temperature (bench top stability) was evaluated for 24 h and 
compared with freshly prepared extracted samples. Freeze and 
thaw stability for three cycles was determined at the same 
concentrations (QC), by thawing at room temperature for 2 - 6 h 
and then refreezing at -20°C for 12 - 24 h. The long term stability of 
ZER at the same QC values was assessed by carrying out the 
experiment after 15 days of the storage in -30°C. The concentration 
of ZER after each storage period was related to the initial 






The robustness of a method is its capability to remain unaffected by 
small, but deliberate variations in method parameters. The effect of 
percent organic strength as well as the buffer on resolution was 
studied by varying acetonitrile from -1 to +1%, methanol from -2 to 
+2% and 0.01 M KH2PO4 from -1 to +1% while the other mobile 
phase components were remained constant as stated in 
chromatographic condition. The flow rate was changed by ± 0.2 
units while the other mobile phase components were remained 
constant as stated in chromatographic condition. The column 
temperature was also studied in such a way that the temperature 
was studied at ambient, 25 and 30°C. 
 
 
RESULTS AND DISCUSSION  
 
The chromatographic conditions and sample preparation 
for the proposed analytical procedure  were  optimized  to 
be suitable for preclinical pharmacokinetic studies. The 
main challenge here is to use the smallest plasma 
volume as much as you can in order to avoid the risk of 
contamination and poor recovery as well. Unlike solid 
phase extraction for purification of plasma samples for 
HPLC analysis that needs more plasma volumes (Cao et 
al., 2008), protein precipitation by acetonitrile is simple, 
not tedious and less risky for the analyst. As shown in the 
chromatograms of human plasma (Figure 2), the 
retention times were 4.5 and 8.89 min for HUM and ZER 
respectively, with a total run time of less than 10 min. The 
analytical process of ZER and HUM were resolved with 
good symmetry. No interfering peaks were observed in 
individual blank plasma at the retention time of ZER and 
HUM, thus confirming the specificity of the method. 
System suitability parameters for the method were as 
follows: the theoretical plates of ZER and HUM were 
8530, 4608, respectively. Tailing factors was less than 
1.6 for both ZER and HUM and resolution between ZER 
and HUM was 11.6.  
The peak area ratio of ZER to HUM was used for the 
quantification of ZER in human plasma samples. Figure 
3, the mean of five calibration curves made over a period 
of 14 days, each calibration curve originating from a new 
set of extraction. The mean calibration curve was linear in 
the concentration range of 2 - 15 µg/ml and equation of 
the six points was y = 0.1948X – 0.0862 with correlation 
coefficient (r) of 0.9978. The accuracy and precision were 
evaluated with QC samples at concentrations of 3, 7 and 
12 µg/ml. The intra-day precision (expressed as 
percentage error RE) was deter-mined by the analysis of 
three replicates of QC samples at three different 
concentrations. The inter-day accuracy and precision 
were determined on three different days and the results 
were shown in Table 1. The intra-day and inter-day of the 
QC values were satisfactory with C.V% less than 10% 
and accuracy with RE within ±3%.  
The lower LOQ was calculated by determining the 
concentration of four spiked calibration standards and 
was found to be 2 µg/ml for ZER in human plasma with 
CV of less 20% and the accuracy of 88 - 112%. The limit 
of detection (LOD) was determined to be 1.5 µg/ml based 
on signal to noise ratio (s/n) ratio of 3:1. The extraction 
recovery was determined by standard addition at three 
different concentrations (3, 7 and 12 µg/ml) for ZER and 
one concentration (10 µg/ml) for HUM and was found to 
be 95 ± 3, 97 ± 1 and 96 ± 2 for ZER and 92 ± 3 for HUM, 
Table 2. The   recovery   of   ZER   using   the   described  




Table 2. ZER recovery and accuracy of the assay.  
 
Absolute recovery Accuracy (%) Conc.(µ
g/ml) Conc. (µg/ml) 
(Mean ± SD) 
Mean (% )±SD 
(n = 3) 
Range 
(min - max) 
C.V.% Mean ±SD 
(n = 3) 
Range 
(min - max) 
C.V.% 
3 2.71 ± 0.24 95.44 ± 3.4 93 - 99 4 94 ± 6 90 - 100 6 
7 6.69 ± 0.12 97.00 ±1.2 89 - 92 1 97 ± 3 94 - 101 3 






Figure 2. Typical chromatograms of human plasma (drug free) (A), blank plasma spiked with ZER (2 µg/ml) 
(B) and human plasma spiked with 10 µg/ml of ZER and 10 µg/ml of HUM. 




Table 3. Stability of ZER in three different concentrations at three different conditions (bench top, freezing and 
thawing cycles and long term storage). 
 
Stability  Spiked Conc. (µg/ml) 
Calculated Conc (µg/ml) 
Mean ±SD(n = 3) 
Average % % C.V. 
3 2.99 ± 0.07 96 2 
7 6.64 ± 0.50 95 8 Bench Topa   
12 10.27 ± 0.14 88 1 
3 2.97 ± 0.04 97 1 
7 6.63 ± 0.57 94 9 Freeze and Thawb   
12 10.79 ± 0.70 90 3 
3 NTd NTd NTd 
7 6.5 ± 0.30 93 5 Long Termc   
12 10.4 ± 0.70 87 7 
 
aAfter 24 h at room temperature.  
 bAfter three freeze thaw cycles.  
c After 15 days at -30°C. 




Table 4. The robustness data of the assay method.  
 
RT (min) Tailing Factor Plates Parameter Modification 
ZER HUM ZER HUM ZER HUM 
Resolution 
53:26:21 9.27 4.41 1.2 1.3 7511 3844 13.80 
55:25:20 8.75 4.39 1.5 1.0 6615 3721 12.00 
Mobile phase 
ratios  
MeOH:ACN:Buffer 57:24:19 10.09 4.9 1.3 1.3 12723 4624 14.60 
0.80 11.09 5.54 1.2 1.0 10404 5929 10.06 
1.00 8.75 4.39 0.7 1.4 9526 6615 9.00 Flow rate (ml/min)  
1.20 7.36 3.69 1.3 1.5 6790 4624 11.56 
Ambient 8.89 4.44 1.5 0.8 6833 3844 12.40 
25 8.69 4.38 1.3 1.0 9526 3721 13.33 Column Temp. (°C)  




method was consistent and efficient. 
Analysis of the stock solution was performed at 200 
µg/ml and after storage for two weeks at 4°C and at room 
temperature for 24 h, more than 99% of ZER remained 
unchanged, based on the peak areas in comparison with 
freshly prepared solution of ZER (200 µg/ml). Thus, ZER 
in standard solution was stable at least 14 days when 
store at 4°C and for 24 h at room temperature. Bench top 
stability of ZER was investigated at the concentration of 
3, 7 and 12 µg/ml and the results revealed that the ZER 
in plasma was stable for at least 24 h with average 
percentage of 96, 95 and 88% respectively. Repeated 
freezing and thawing (three cycles) of plasma samples 
spiked with ZER at three levels (3, 7, 12 µg/ml) showed a 
mean percentage concentration of 97, 94 and 90%, 
respectively. Long term stability of ZER in plasma at -30 
was also performed after 15 days of storage at three 
levels (3, 7, 12 µg/ml), which showed mean percentage 
concentration of (non-tested, vial was broken), 93, 87% 
respectively. The results of the stability study was 
presented in Table 3 and indicated that  ZER  was  stable  
in the studied conditions. 
The robustness results are shown in Table 4. It can be 
seen that the chromatographic conditions in accordance 
with established value (Shah et al., 2000). A change in 
mobile phase composition (acetonitrile 25 ± 1% v/v), 
(methanol 55 ± 2% v/v), (0.01 M KH2 PO4 20 ± 1% v/v), 
flow rate (1 ± 0.2 units) and column temperature (ambient, 
25 and 30°C) had no impact on chromatographic perfor-
mance. The tailing factor for both ZER and HUM was less 
than 2 and the two analytes (ZER and HUM) were well 
separated under the conditions carried out. The 
resolution between ZER and HUM was ranged 9.0 - 14.6. 
Considering the result of modifications in the system 
suitability parameters and the specificity of the method, it 











ZER in micro-volumes human plasma (| 1.5 ml) was 
found to be simple, accurate, specific and robust. The 
method consisted of one step plasma protein preci-
pitation using acetonitrile, followed by chromatographic 
separation in photodiode detector. No interference peaks 
were observed at the retention time of both ZER and 
HUM. This method could therefore be recommended for 
in vivo analysis of ZER for preclinical pharmacokinetic 
study and may also be applied for the estimation of ZER 
in other biological fluids such as serum and tissues after 
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